• Compare Products
Menu
Account
Make more informed purchasing decisions with our new product availability and delivery estimate feature, now available on all product pages, in your cart, and during checkout.

EasySep™ Release Human CD3 Positive Selection Kit

Immunomagnetic positive selection of human CD3+ cells using particle release technology

Loading...
 
New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more

EasySep™ Release Human CD3 Positive Selection Kit

Immunomagnetic positive selection of human CD3+ cells using particle release technology

From: 880 USD
Catalog #
(Select a product)
Immunomagnetic positive selection of human CD3+ cells using particle release technology
Add to Wish List

Product Advantages


  • Highly purified human CD3+ cells isolated in less than 30 minutes

  • No-wash removal of EasySep™ Releasable RapidSpheres™

What's Included

  • EasySep™ Release Human CD3 Positive Selection Kit (Catalog #17751)
    • EasySep™ Release Human CD3 Positive Selection Cocktail, 1 mL
    • EasySep™ Releasable RapidSpheres™ 50201, 1 mL
    • EasySep™ Release Buffer (Concentrate), 3 x 1 mL
  • RoboSep™ Human CD3 Positive Selection Kit (Catalog #17751RF)
    • EasySep™ Release Human CD3 Positive Selection Cocktail, 1 mL
    • EasySep™ Releasable RapidSpheres™, 1 mL
    • EasySep™ Release Buffer (Concentrate), 3 x 1 mL
    • RoboSep™ Buffer (Catalog #20104)
    • RoboSep™ Filter Tips (Catalog #20125)
Products for Your Protocol
To see all required products for your protocol, please consult the Protocols and Documentation.
  1. EasySep™ Magnet
    EasySep™ Magnet

    Magnet for column-free immunomagnetic separation

  2. EasySep™ Buffer
    EasySep™ Buffer

    Cell separation buffer

Overview

Easily isolate highly purified and magnetic particle-free human CD3+ cells from fresh or previously frozen peripheral blood mononuclear cells (PBMCs) or washed leukapheresis samples by immunomagnetic positive selection, with the EasySep™ Release Human CD3 Positive Selection Kit. Widely used in published research for more than 20 years, EasySep™ combines the specificity of monoclonal antibodies with the simplicity of a column-free magnetic system.

In this EasySep™ positive selection procedure, desired cells are first labeled with antibody complexes recognizing CD3 and magnetic particles called EasySep™ Releasable RapidSpheres™. Unlike traditional magnetic particles, which stay bound to the target cells, these RapidSpheres™ have a releasable feature. After separation using an EasySep™ magnet, bound magnetic particles are removed from the EasySep™-isolated CD3+ cells using a release agent, and unwanted non-CD3+ cells are targeted for depletion. The final isolated fraction contains highly purified CD3+ cells that are immediately ready for downstream applications such as flow cytometry, culture, or DNA/RNA extraction. Following cell isolation with this EasySep™ kit, antibody complexes remain bound to the cell surface and may interact with Brilliant Violet™ antibody conjugates, polyethylene glycol-modified proteins, or other chemically related ligands. The CD3 antigen is expressed on all T cells and CD56+ NKT cells.

This kit is designed for cell therapy research applications, but may be qualified for use as an ancillary material following the framework outlined in USP<1043>. STEMCELL can work with you to qualify this reagent as an ancillary material under an approved investigational new drug (IND) or clinical trial application (CTA). Learn more about how we can support your regulatory needs here.

Learn more about how immunomagnetic EasySep™ technology works or how to fully automate immunomagnetic cell isolation with RoboSep™. Explore additional products optimized for your workflow, including those for culture media, supplements, antibodies, and more.


Magnet Compatibility
• EasySep™ Magnet (Catalog #18000)
• “The Big Easy” EasySep™ Magnet (Catalog #18001)
• EasyPlate™ Magnet (Catalog #18102)
• EasyEights™ Magnet (Catalog #18103)
• RoboSep™-S (Catalog #21000)
Subtype
Cell Isolation Kits
Cell Type
T Cells
Species
Human
Sample Source
Leukapheresis, PBMC
Selection Method
Positive
Brand
EasySep, RoboSep
Area of Interest
Immunology, Cell Therapy Development

Data Figures

Typical EasySep™ Release Human CD3 Positive Selection Profile

Figure 1. Typical EasySep™ Release Human CD3 Positive Selection Profile

Starting with a single-cell suspension of human PBMCs, the CD3+ cell content of the isolated fraction is typically 98.7 ± 0.9% (mean ± SD) using the purple EasySep™ Magnet. In the above example, the purities of the start and final isolated fractions are 38.4% and 99.0%, respectively.

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Information Sheet
Product Name
EasySep™ Release Human CD3 Positive Selection Kit
Catalog #
17751
Lot #
All
Language
English
Document Type
Product Information Sheet
Product Name
RoboSep™ Release Human CD3 Positive Selection Kit
Catalog #
17751RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Product Name
EasySep™ Release Human CD3 Positive Selection Kit
Catalog #
17751
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Product Name
EasySep™ Release Human CD3 Positive Selection Kit
Catalog #
17751
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Product Name
EasySep™ Release Human CD3 Positive Selection Kit
Catalog #
17751
Lot #
All
Language
English
Document Type
Safety Data Sheet 4
Product Name
EasySep™ Release Human CD3 Positive Selection Kit
Catalog #
17751
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Product Name
RoboSep™ Release Human CD3 Positive Selection Kit
Catalog #
17751RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Product Name
RoboSep™ Release Human CD3 Positive Selection Kit
Catalog #
17751RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Product Name
RoboSep™ Release Human CD3 Positive Selection Kit
Catalog #
17751RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 4
Product Name
RoboSep™ Release Human CD3 Positive Selection Kit
Catalog #
17751RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 5
Product Name
RoboSep™ Release Human CD3 Positive Selection Kit
Catalog #
17751RF
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Research Area
Workflow Stages

Resources and Publications

Educational Materials (11)

Tools for Your Immunology Research
Brochure
Tools for Your Immunology Research
T Cell Reagents for Your Cellular Therapy Research
Brochure
T Cell Reagents for Your Cellular Therapy Research
EasySep™ Cell Separation Technology
Brochure
EasySep™ Cell Separation Technology
EasySep™ Release Free Your Positively Selected Cells from Magnetic Particles
Brochure
EasySep™ Release Free Your Positively Selected Cells from Magnetic Particles
Human Immune Cytokines
Wallchart
Human Immune Cytokines
Production of Chimeric Antigen Receptor T Cells
Wallchart
Production of Chimeric Antigen Receptor T Cells
Frequencies of Human Cell Types in Blood-Related Sources
Wallchart
Frequencies of Human Cell Types in Blood-Related Sources
How EasySep™ Magnetic Cell Separation Technology Works: Fast and Easy Cell Isolation
1:57
Video
How EasySep™ Magnetic Cell Separation Technology Works: Fast and Easy Cell Isolation
CAR T Cell Manufacturing Workflow: Isolation, Activation and Expansion
0:59
Video
CAR T Cell Manufacturing Workflow: Isolation, Activation and Expansion
Simultaneous Cell Isolation from Multiple Samples Using the EasyEights™ EasySep™ Magnet
0:57
Video
Simultaneous Cell Isolation from Multiple Samples Using the EasyEights™ EasySep™ Magnet
Releasable RapidSpheres Enable Immunomagnetic Purification of Highly Viable and Functional Immune Cells from Complex Tissues in Less Than 30 Minutes
Scientific Poster
Releasable RapidSpheres Enable Immunomagnetic Purification of Highly Viable and Functional Immune Ce...

Publications (2)

Metformin sensitizes leukemic cells to cytotoxic lymphocytes by increasing expression of intercellular adhesion molecule-1 (ICAM-1). N. Allende-Vega et al. Scientific reports 2022 jan

Abstract

Solid tumor cells have an altered metabolism that can protect them from cytotoxic lymphocytes. The anti-diabetic drug metformin modifies tumor cell metabolism and several clinical trials are testing its effectiveness for the treatment of solid cancers. The use of metformin in hematologic cancers has received much less attention, although allogeneic cytotoxic lymphocytes are very effective against these tumors. We show here that metformin induces expression of Natural Killer G2-D (NKG2D) ligands (NKG2DL) and intercellular adhesion molecule-1 (ICAM-1), a ligand of the lymphocyte function-associated antigen 1 (LFA-1). This leads to enhance sensitivity to cytotoxic lymphocytes. Overexpression of anti-apoptotic Bcl-2 family members decrease both metformin effects. The sensitization to activated cytotoxic lymphocytes is mainly mediated by the increase on ICAM-1 levels, which favors cytotoxic lymphocytes binding to tumor cells. Finally, metformin decreases the growth of human hematological tumor cells in xenograft models, mainly in presence of monoclonal antibodies that recognize tumor antigens. Our results suggest that metformin could improve cytotoxic lymphocyte-mediated therapy.
View publication
CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia. X. Wang et al. Leukemia 2022 apr

Abstract

Chimeric antigen receptor (CAR) T cells targeting CD19 mediate potent antitumor effects in B-cell malignancies including acute lymphoblastic leukemia (ALL), but antigen loss remains the major cause of treatment failure. To mitigate antigen escape and potentially improve the durability of remission, we developed a dual-targeting approach using an optimized, bispecific CAR construct that targets both CD19 and BAFF-R. CD19/BAFF-R dual CAR T cells exhibited antigen-specific cytokine release, degranulation, and cytotoxicity against both CD19-/- and BAFF-R-/- variant human ALL cells in vitro. Immunodeficient mice engrafted with mixed CD19-/- and BAFF-R-/- variant ALL cells and treated with a single dose of CD19/BAFF-R dual CAR T cells experienced complete eradication of both CD19-/- and BAFF-R-/- ALL variants, whereas mice treated with monospecific CD19 or BAFF-R CAR T cells succumbed to outgrowths of CD19-/BAFF-R+ or CD19+/BAFF-R- tumors, respectively. Further, CD19/BAFF-R dual CAR T cells showed prolonged in vivo persistence, raising the possibility that these cells may have the potential to promote durable remissions. Together, our data support clinical translation of BAFF-R/CD19 dual CAR T cells to treat ALL.
View publication
View All Publications

Related Products

Related Products

Labeling Antibodies

New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more
Quality Statement:

PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.

Copyright © 2025 by STEMCELL Technologies. All rights reserved.